AR024146A1 - Derivados de 4-fenil-pirimidina - Google Patents

Derivados de 4-fenil-pirimidina

Info

Publication number
AR024146A1
AR024146A1 ARP000102643A ARP000102643A AR024146A1 AR 024146 A1 AR024146 A1 AR 024146A1 AR P000102643 A ARP000102643 A AR P000102643A AR P000102643 A ARP000102643 A AR P000102643A AR 024146 A1 AR024146 A1 AR 024146A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
hydrogen
halogen
phenyl
morpholinyl
Prior art date
Application number
ARP000102643A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR024146A1 publication Critical patent/AR024146A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de la formula general (1) en donde: R1 es hidrogeno o halogeno; R2 es hidrogeno, halogeno, alquilo inferior o alcoxilo inferior; R1 y R2 puedenser junto con los dos átomos de C del anillo -CH=CH-CH=CH-; R3 es halogeno, trifluorometilo, alquilo inferior o alcoxilo inferior; R4 y R4 sonindependientemente uno de otro hidrogeno o alquilo inferior; R5 es alquilo inferior, alcoxilo inferior, amino, fenilo, hidroxi-alquilo inferior, ciano-alquiloinferior, carbamoílo-alquilo inferior, piridilo, pirimidilo, -(CH2)n-piperazinilo, el cual se encuentra substituído opcionalmente por uno o dos grupos alquiloinferior o por hidroxi-alquilo inferior, -(CH2)n-morfolinilo, -(CH2)n-piperidinilo, -(CH2)n+1-imidazolilo, alquilo inferior-sulfanilo, alquiloinferior-sulfonilo, bencilamino, -NH-(CH2)n+1N(R4)2, -(CH2)n+1N(R4)2, -O-(CH2)n+1-morfolinilo, -O-(CH2)n+1-piperidinilo o -O-(CH2)n+1N(R4)2, donde R4es hidrogeno o alquilo inferior; y n es 0-2; X es -C(O)N(R4)- o -N(R4)C(O)-; y sales derivadas deuna adicion ácida farmacéuticamente aceptables. Se hademostrado que los compuestos anteriormente mencionados tienen una buena afinidad por el receptor de NK-1 y por lo tanto, pueden ser utilizados para eltratamiento de enfermedades relacionadas coneste receptor.
ARP000102643A 1999-05-31 2000-05-29 Derivados de 4-fenil-pirimidina AR024146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99110483 1999-05-31

Publications (1)

Publication Number Publication Date
AR024146A1 true AR024146A1 (es) 2002-09-04

Family

ID=8238271

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102643A AR024146A1 (es) 1999-05-31 2000-05-29 Derivados de 4-fenil-pirimidina

Country Status (36)

Country Link
US (1) US6274588B1 (es)
EP (1) EP1187815B1 (es)
JP (1) JP3590592B2 (es)
KR (1) KR100440106B1 (es)
CN (1) CN1166643C (es)
AR (1) AR024146A1 (es)
AT (1) ATE317389T1 (es)
AU (1) AU770786B2 (es)
BR (1) BR0011127A (es)
CA (1) CA2375671C (es)
CO (1) CO5170520A1 (es)
CZ (1) CZ20014271A3 (es)
DE (1) DE60025918T2 (es)
DK (1) DK1187815T3 (es)
ES (1) ES2257294T3 (es)
GC (1) GC0000191A (es)
HK (1) HK1046528B (es)
HR (1) HRP20010871A2 (es)
HU (1) HUP0201315A3 (es)
IL (2) IL146460A0 (es)
JO (1) JO2261B1 (es)
MA (1) MA26793A1 (es)
MX (1) MXPA01012089A (es)
MY (1) MY122731A (es)
NO (1) NO321354B1 (es)
NZ (1) NZ515407A (es)
PE (1) PE20010153A1 (es)
PL (1) PL353441A1 (es)
PT (1) PT1187815E (es)
RU (1) RU2243221C2 (es)
SI (1) SI1187815T1 (es)
TR (1) TR200103457T2 (es)
TW (1) TW550258B (es)
WO (1) WO2000073279A1 (es)
YU (1) YU84901A (es)
ZA (1) ZA200109163B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
AU2001284504A1 (en) * 2000-09-14 2002-03-26 Ajinomoto Co., Inc. Novel pyrimidine derivative and novel pyridine derivative
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
EP1679309A4 (en) * 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
HUP0400405A3 (en) * 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
WO2006050476A2 (en) * 2004-11-03 2006-05-11 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
CA2601935C (en) * 2005-02-22 2013-04-09 F. Hoffmann-La Roche Ag Nk1 antagonists
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
EP1890703B1 (en) * 2005-06-14 2016-05-11 Taigen Biotechnology Pyrimidine compounds as chemokine receptors inhibitors
US8372849B2 (en) 2008-04-21 2013-02-12 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
EP3250034B1 (en) * 2015-01-30 2020-03-11 Basf Se Herbicidal phenylpyrimidines
KR102335082B1 (ko) * 2017-01-10 2021-12-06 내셔날 헬스 리서치 인스티튜트 헤테로사이클릭 화합물 및 이의 용도
KR102006547B1 (ko) * 2017-11-16 2019-08-01 서울대학교산학협력단 벤즈아미드 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 염증질환의 치료 또는 예방용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698340A (en) 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
DE3614060A1 (de) * 1986-04-23 1987-10-29 Schering Ag Pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
BR9408442A (pt) 1993-12-29 1997-08-05 Merck Sharp & Dohme Composto composição farmacêutica processos para tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquiquininas e para a preparação do composto e de uso do composto
JPH11512399A (ja) 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ，インコーポレイテッド ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
US6274588B1 (en) 2001-08-14
JP2003500478A (ja) 2003-01-07
BR0011127A (pt) 2002-02-19
MA26793A1 (fr) 2004-12-20
HRP20010871A2 (en) 2003-04-30
EP1187815B1 (en) 2006-02-08
HUP0201315A3 (en) 2003-02-28
DE60025918T2 (de) 2006-09-28
PL353441A1 (en) 2003-11-17
TW550258B (en) 2003-09-01
CZ20014271A3 (cs) 2002-05-15
NZ515407A (en) 2004-03-26
JO2261B1 (en) 2004-10-07
CN1353697A (zh) 2002-06-12
CA2375671C (en) 2009-08-25
ATE317389T1 (de) 2006-02-15
IL146460A (en) 2006-10-31
KR20020000826A (ko) 2002-01-05
JP3590592B2 (ja) 2004-11-17
NO20015700D0 (no) 2001-11-22
YU84901A (sh) 2004-09-03
AU770786B2 (en) 2004-03-04
ZA200109163B (en) 2003-02-06
MXPA01012089A (es) 2002-06-04
HUP0201315A2 (hu) 2002-12-28
AU4567700A (en) 2000-12-18
DE60025918D1 (de) 2006-04-20
SI1187815T1 (sl) 2006-06-30
ES2257294T3 (es) 2006-08-01
NO321354B1 (no) 2006-05-02
CO5170520A1 (es) 2002-06-27
IL146460A0 (en) 2002-07-25
MY122731A (en) 2006-04-29
GC0000191A (en) 2006-03-29
EP1187815A1 (en) 2002-03-20
WO2000073279A1 (en) 2000-12-07
TR200103457T2 (tr) 2002-04-22
NO20015700L (no) 2001-11-22
PE20010153A1 (es) 2001-02-08
CN1166643C (zh) 2004-09-15
KR100440106B1 (ko) 2004-07-14
PT1187815E (pt) 2006-06-30
CA2375671A1 (en) 2000-12-07
HK1046528A1 (en) 2003-01-17
RU2243221C2 (ru) 2004-12-27
HK1046528B (zh) 2005-02-25
DK1187815T3 (da) 2006-06-19

Similar Documents

Publication Publication Date Title
AR024146A1 (es) Derivados de 4-fenil-pirimidina
KR970704435A (ko) 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands)
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
SE0104332D0 (sv) Therapeutic agents
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
MY137156A (en) Dual nk1/nk3 derivatives
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
SE0104334D0 (sv) Therapeutic agents
GB0226724D0 (en) Therapeutic agents
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
WO1993014084A3 (en) Piperidine derivatives
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
AR024145A1 (es) Derivados de 5-fenil-pirimidina
HUP0203136A2 (hu) Piperazinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HK1068334A1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
BG103984A (en) Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
MXPA04000278A (es) Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
AR051686A1 (es) Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4.
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
JO2696B1 (en) Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal